• May 28, 2024

Unfit for Purpose

 Unfit for Purpose

HPHC testing is an unreliable, misleading comparative measure for premium cigars.

By Gerald Long

An understanding of what scientific content is reliable, meaningful and necessary for the substantial equivalence (SE) reports that tobacco manufacturers are required to submit to the U.S. Food and Drug Administration (FDA) for certain products is much needed and long overdue. The industry will not have an answer until FDA issues the final SE rule currently under review, but the proposed SE rule released last April indicates that data on harmful and potentially harmful constituents (HPHCs) will be required as a comparison point in all SE reports 1  The Family Smoking Prevention and Tobacco Control Act (TCA) requires the industry to report levels of HPHCs in individual products 2. Importantly, however, the TCA does not require HPHC test results to be included in SE reports. Unfortunately, FDA decided to include such results in SE reports as part of the proposed SE rule. This is both unnecessary and misleading when applied to premium cigars, as the industry has explained in extensive comments filed with the agency.

Further, while there is no statutory requirement that SE reports include HPHC data, doing so will not further any legitimate agency objective. FDA plans to use HPHC data as a metric to determine if the subject of an SE report (the “new” product) is substantially equivalent to a predicate product. For premium cigars, however, such test results will be meaningless as a comparative measure, will be crushingly expensive for the industry and will not provide FDA useful information furthering public health. FDA would be making a serious mistake by requiring such test results for premium cigar SE reports.   

The problem

The TCA requires new tobacco products to undergo premarket review by FDA before introduction into interstate commerce. Section 910(a)(1) of the Food Drug  and Cosmetic (FD&C) Act defines a “new tobacco product” as any tobacco product not commercially marketed in the United States as of Feb. 15, 2007, or any modification of a tobacco product where the modified product was commercially marketed in the United States after Feb. 15, 2007. The SE pathway, one of three premarket review pathways for a new tobacco product, is designed to demonstrate that the new tobacco product is “substantially equivalent” to a predicate tobacco product (i.e., one on the U.S. market as of Feb. 15, 2007) 

FDA’s attempt to rely on HPHC data in SE reports for premium cigars is misguided. For one, it ignores difficulties in determining what “comparison criteria” to use for such testing and whether such criteria are reliable. Further, it is unclear what testing methodology to use. There is no internationally recognized, validated method for testing hand-rolled large cigars. Simple t-test data comparisons—a type of inferential statistic used to determine if a difference exists between the means of two groups—when applied to highly variable data collected with unvalidated methods, could lead to the incorrect conclusion that two identical products are different or that two different products are the same. Testing methods and comparison procedures that might solve this problem do not exist.

In addition, the paired designed testing comparisons favored by FDA are not available for premium cigars. Instead, the industry must rely on historical method capability data, such as repeatability and reproducibility, in order to establish what acceptable HPHC differences are between products for SE purposes; however, little, if any, such data exist for premium cigar HPHC methods. In any data comparison approach, allowable differences are critical factors in establishing product equivalence. Further complicating matters, differences in analytes other than nicotine (where the new product has a significantly lower yield than the predicate product) are considered by FDA to “not raise additional questions of public health.”

The absence of utility and reliability of HPHC data is even more glaring for premium cigars. HPHC data for premium cigars as a comparative measure is not reliable or meaningful, given the unique nature and variability of cigar tobacco and the handmade process used to make premium cigars. Also troubling is that, unlike for cigarettes, there are no reference products for premium cigars. This poses an issue with respect to scientific validation of testing methods and data resulting from any premium cigar testing.  

To evaluate the usefulness of HPHC testing on premium cigars as a comparative measure, Tabacalera USA (TUSA) performed extensive HPHC testing of premium cigars from its portfolio. Results demonstrate that HPHC testing “data” is more likely to mislead FDA than help it make informed and scientifically sound comparative decisions4.

2020_03-universal
Advertisement

TUSA’s HPHC testing efforts

TUSA tested 91 products from its commercial inventory. The 91 cigars comprised 43 different sizes and 18 different blends, all of which, like nearly all premium cigars, were comprised entirely of dark air-cured tobaccos. TUSA tested for certain physical measurements (i.e., conditioned weight, length, circumference and pressure drop) using 40 replicates; six individual HPHCs in cigar tobacco using seven replicates; 18 individual HPHCs in cigar smoke using seven replicates; and for TNCO in cigar smoke using 20 replicates (total particulate matter, tar, nicotine, carbon monoxide and water). “Replicates” refers to a “repeat measurement” and gives statistical power to conclusions based on the data. These tests measured HPHCs on FDA’s “abbreviated” list for cigarettes since FDA has not published a list for premium cigars.

TUSA utilized Coresta testing methodology, though it is not validated for large hand-rolled cigars. In fact, there is no internationally recognized, validated smoking methodology for testing large hand-rolled cigars. One problem, for example, is that cigars, especially large cigars, smoked under the Coresta methodology tend to extinguish and need to be relit, altering HPHC results.

One threshold issue in testing HPHCs in cigar tobacco is how to process samples for testing. One option is to combine all cigar tobacco from a sample, grind the tobacco and test samples from the combined composite tobacco, a method typically used with cigarettes. Another option is to grind each cigar separately and test the tobacco from each individually ground cigar. The former option produces consistently low variability within composite samples that can be considered a measure of analytical method variability while the second option provides a measure of the variability between the cigars themselves.

In the testing, TUSA collected more than 36,000 points of data. Such a large pool of data points might superficially lead one to believe the data are reliable and usable as a means to compare cigars. As set forth below, however, these data points confirm that HPHC testing on premium cigars—and the corresponding data—should not be a benchmark for comparative analysis by FDA5

The HPHC test data

Data from TUSA’s HPHC testing confirmed that it does not provide a useful metric of premium cigar comparison for equivalence purposes.

Most critically, 18 out of the 91 tested cigars had the same blend of dark air-cured tobaccos (“Blend A”). Any differences in tobacco HPHCs for the Blend A cigars revealed by testing is attributable only to the natural variability of tobacco. A naive statistical comparison might lead to the conclusion that the cigars are different, but they are not.

As an example, TUSA tested for the HPHC N-nitrosonornicotine (NNN) in cigar tobacco. Test data revealed that the variability of NNN among Blend A cigars was even larger than the variability between completely different cigar blends. In other words, test results identified cigars of the same blend as potentially “more different” from one another than cigars with completely different tobacco blends. Figure 1 shows this in a graphic form, making the huge variability apparent.

Figure 1

Box plot of tobacco NNN (µg/g cigar) for 91 samples tested segregated into 18 samples with Blend A and the other 73 samples

The data was also concerning with respect to the testing of cigar smoke. Notably, at present, smoke testing methodologies that yield reliable, reproducible and scientifically valid results for HPHCs in large hand-rolled cigars do not exist. The data from TUSA’s smoke testing makes it clear that such testing is meaningless as a comparative measure. With the exception of certain “extreme” cigar sizes, the range of HPHCs in the smoke from Blend A cigars (comprising only 18 different cigar sizes) was just as large as the range of smoke HPHCs in the entire study set of 91 cigars, covering 18 different blends and 43 different cigar sizes. There was also no real consistency or discrimination for smoke yield between cigars of different diameters. Figure 2 shows an example using only data for carbon monoxide (CO). The variability, between both sizes and blends, is clear.

Figure 2

Box plot of smoke carbon monoxide (mg/cigar) for 91 samples segregated into the Blend A samples with 18 different sizes and the other 73 samples in 34 sizes

Statistical comparisons of this data would conclude that, excluding extremely large or small sizes, all smoke CO results for the entire study set fall within the range of 200 mg/cigar to 1,100 mg/cigar defined by the 18 sizes from the Blend A group. The variabilities in fundamental design characteristics like cigar weight and size, inherent to handmade cigars and the uncharacterized variabilities in premium cigar smoking methods directly influence the observed variabilities in smoke HPHC deliveries.

The takeaway

HPHCs, in tobacco or smoke, are simply not viable metrics for comparing premium handmade cigars. Unlike cigarettes, produced by a high-speed, mechanized manufacturing process, premium cigars are handmade, artisan products with significant natural variability in the tobacco. Further, natural variability in tobacco means that the same cigar may vary in ways HPHC testing cannot account for, making the HPHC data of no utility as a comparative measure. Other variabilities in fundamental design characteristics, such as cigar weight and size, also directly influence observed variabilities in smoke HPHC deliveries.

A comparison of cigars based upon HPHC results could lead to the erroneous conclusion that the cigars have different characteristics when they do not or that they do not have different characteristics when they do. For premium cigars, different HPHC levels in the tobacco or in the smoke do not allow for conclusions on whether or not the cigars are “substantially equivalent.”

FDA cannot and should not look to differences in HPHC results for premium cigars because of a high likelihood of erroneous conclusions in equivalence comparisons. HPHC results for premium cigars are confounded by inherent variability of cigar tobacco, variability resulting from handmade construction and uncharacterized variabilities in cigar smoking methods.

The industry has raised this issue with FDA, including in comments on the proposed SE rule. The bottom line is that HPHCs are simply and clearly not a viable metric for distinguishing between premium cigars. As Albert Einstein said, “Not everything that can be counted counts, and not everything that counts can be counted.”

2020_03-swm
Advertisement

References


1See Content and Format of Substantial Equivalence Reports; Food and Drug Administration Actions on Substantial Equivalence Reports, 84 Fed. Reg. 12,740 (proposed April 2, 2019) (to be codified at 21 C.F.R. pt. 16, 1107).


2Tobacco Control Act, 21 U.S.C.A. § 387 (2009). FDA published a preliminary list of 93 HPHCs in March 2012 and then identified product-specific subsets of HPHCs for which manufacturers and importers are to test and report to FDA. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug and Cosmetic Act, March 2012.


3See Tobacco Control Act, 21 U.S.C.A. §905(j)(1)(A). 


4TUSA defines a premium cigar as a cigar with the following characteristics: is wrapped in whole leaf tobacco; contains a 100 percent leaf tobacco binder; is made by manually combining the wrapper, filler and binder; has no filter, tip or nontobacco mouthpiece and is capped by hand; and weighs more than 6 pounds per 1,000 units. TUSA has proposed this definition of premium cigar to FDA on multiple occasions.


5Recent work published by the Center for Tobacco Products and other researchers confirms the variability in any testing among cigars of like brands and sizes. This work did not attempt smoke testing; rather, it examined only product size, dry nicotine content and tobacco pH, and the study found a “wide variation in product size and nicotine content within the domestic cigar market.” Further, the study found that “cigar size does not necessarily correlate with nicotine or free nicotine content.” Critically, the study found that it was not possible to replicate results, noting, “in the two large cigar and cigarillo brands analyzed a second time, there was considerable within-brand variance in nicotine content and concentration between the first and second analyses.” See Koszowski, et al. Nicotine Content and Physical Content of Large Cigars and Cigarillos in the United States. Nicotine and Tob. Res. 20(3) 393-398 (2018).